タシマ ユウコ   Tashima Yuko
  田嶋 裕子
   所属   産業医科大学病院  診療科 呼吸器・胸部外科
   職種   助教
言語種別 英語
発表タイトル IS2-6 The 25 cases of heart and great vessel resection innonsmallcelllungcancerpatients
会議名 第33回日本呼吸器外科学会総会
学会区分 全国規模の学会
発表形式 口頭
講演区分 一般
発表者・共同発表者KojiKuroda,SyuichiShinohara,RintaroOyama,KenichiKobayashi,SakikoYura, HirokiMatsumiya,TaijiKuwata,MasaruTakenaka,YasuhiroChikaishi,SoichiOka, AyakoHirai,KazueYoneda,YukoTashima,YoshikaNagata,NaokoImanishi, FumihiroTanaka
発表年月日 2016/05/13
開催地
(都市, 国名)
京都市/国立京都国際会館
学会抄録 日本呼吸器外科学会学術総会 30(3),36 2016
概要 Abstract Weanalyzedtheresultsofsurgicaltreatmentthathavebeenresectedtheheartandgreatvesselsfornonsmall cell lung cancer in our department from August 2011 to September 2015.The operators have determinedheartandgreatvesselsresectionwasnecessaryforcompleteresection.Greatvesselswerethesitesof that have been recognized as T4 great vessels in the lung cancer handling Terms seventh edition. Surgery related death and hospitality death were none. Heart and great vessels resection sites were left atrium 9/superiorvenacava8/pulmonaryvein(intrapericardium)7/rightbrachiocephalicvein1cases.ThecaseswereSex ratio male 18/Female 7, 4481 years of age(mean 62.9 years), right and left ratio 19/6,pathological type Sq 14/Ad 9/LCNEC 1/Ad+Sq 1, the tumor diameter 16110mm(average 48mm), preoperative treatment 9 (CRT8)/none16cases. Clinical stage was T1a/1b/2a/2b/3/4=1/2/8/4/0/8, N0/1/2/3=6/6/13/0, M0/1a/1b= 0/0/1cases.SurgicalprocedureswereRUL7(sleeve1)/RML1/RLL3(sleeve1)/RMLL4/RUML 3/RPN 1 andLUL5(sleeve3)/LPN1cases.ThePathologicalstagewasT1a/1b/2a/2b/3/4=2/2/10(y2a2)/1/0/7,N 0/1/2/3=9(y03)/7(y11)/9(y25)/0,M0/1a/1b=0/0/1.PreoperativetherapeuticeffectwasEf1a/1b/2/3 =0/4/4/1.SurvivalwascalculatedbytheKaplanMeiermethod.Observationperiodis771561days(average observationperiod607days).9caseswithoutrecurrence(36%),16caseswerewithrecurrence(64%).Resectionsitesthatshowednorecurrenceweresuperiorvenacava3andleftatrium2,pulmonaryvein4cases.Relapsefree survival was median 330 days, 1year recurrencefree survival 44%, 2year recurrencefree survival30%.Foroverallsurvival,1yearsurvivalratewas87%,2yearsurvivalrate61%.